Insulin detemir: A long-acting insulin analog for the treatment of Type 1 and 2 diabetes

Research output: Contribution to journalArticle

Abstract

Many patients are apprehensive about initiating insulin. Worries about injections, hypoglycemia and weight gain as a result of insulin therapy may contribute to their concerns, and consequently pose a challenge to achieving or maintaining optimal glycemic control. Basal insulin replacement has proven to be effective and safe for initiating insulin therapy in Type 2 diabetes. With increasing β-cell dysfunction, the addition of rapid-acting prandial insulin to basal insulin therapy represents the gold standard for physiologic insulin replacement. Insulin detemir's beneficial profile in terms of offering less weight gain and a reduced risk of hypoglycemic episodes compared with neutral protamine Hagedorn insulin makes it an attractive alternative for basal insulin therapy. This review provides a comprehensive update on the pharmacology, clinical efficacy and safety of insulin detemir in Type 1 and 2 diabetes.

Original languageEnglish (US)
Pages (from-to)513-529
Number of pages17
JournalTherapy
Volume5
Issue number4
DOIs
StatePublished - 2008

Fingerprint

Long-Acting Insulin
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Insulin
Therapeutics
Weight Gain
Short-Acting Insulin
Isophane Insulin
Insulin Detemir
Hypoglycemia
Hypoglycemic Agents
Meals
Pharmacology
Safety
Injections

Keywords

  • Basal insulin
  • Insulin detemir
  • Insulin glargine
  • NPH insulin
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Insulin detemir : A long-acting insulin analog for the treatment of Type 1 and 2 diabetes. / Meneghini, Luigi F.

In: Therapy, Vol. 5, No. 4, 2008, p. 513-529.

Research output: Contribution to journalArticle

@article{dc7f721f98ee4081a5f067eb96b5d87d,
title = "Insulin detemir: A long-acting insulin analog for the treatment of Type 1 and 2 diabetes",
abstract = "Many patients are apprehensive about initiating insulin. Worries about injections, hypoglycemia and weight gain as a result of insulin therapy may contribute to their concerns, and consequently pose a challenge to achieving or maintaining optimal glycemic control. Basal insulin replacement has proven to be effective and safe for initiating insulin therapy in Type 2 diabetes. With increasing β-cell dysfunction, the addition of rapid-acting prandial insulin to basal insulin therapy represents the gold standard for physiologic insulin replacement. Insulin detemir's beneficial profile in terms of offering less weight gain and a reduced risk of hypoglycemic episodes compared with neutral protamine Hagedorn insulin makes it an attractive alternative for basal insulin therapy. This review provides a comprehensive update on the pharmacology, clinical efficacy and safety of insulin detemir in Type 1 and 2 diabetes.",
keywords = "Basal insulin, Insulin detemir, Insulin glargine, NPH insulin, Type 1 diabetes, Type 2 diabetes",
author = "Meneghini, {Luigi F.}",
year = "2008",
doi = "10.2217/14750708.5.4.513",
language = "English (US)",
volume = "5",
pages = "513--529",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Insulin detemir

T2 - A long-acting insulin analog for the treatment of Type 1 and 2 diabetes

AU - Meneghini, Luigi F.

PY - 2008

Y1 - 2008

N2 - Many patients are apprehensive about initiating insulin. Worries about injections, hypoglycemia and weight gain as a result of insulin therapy may contribute to their concerns, and consequently pose a challenge to achieving or maintaining optimal glycemic control. Basal insulin replacement has proven to be effective and safe for initiating insulin therapy in Type 2 diabetes. With increasing β-cell dysfunction, the addition of rapid-acting prandial insulin to basal insulin therapy represents the gold standard for physiologic insulin replacement. Insulin detemir's beneficial profile in terms of offering less weight gain and a reduced risk of hypoglycemic episodes compared with neutral protamine Hagedorn insulin makes it an attractive alternative for basal insulin therapy. This review provides a comprehensive update on the pharmacology, clinical efficacy and safety of insulin detemir in Type 1 and 2 diabetes.

AB - Many patients are apprehensive about initiating insulin. Worries about injections, hypoglycemia and weight gain as a result of insulin therapy may contribute to their concerns, and consequently pose a challenge to achieving or maintaining optimal glycemic control. Basal insulin replacement has proven to be effective and safe for initiating insulin therapy in Type 2 diabetes. With increasing β-cell dysfunction, the addition of rapid-acting prandial insulin to basal insulin therapy represents the gold standard for physiologic insulin replacement. Insulin detemir's beneficial profile in terms of offering less weight gain and a reduced risk of hypoglycemic episodes compared with neutral protamine Hagedorn insulin makes it an attractive alternative for basal insulin therapy. This review provides a comprehensive update on the pharmacology, clinical efficacy and safety of insulin detemir in Type 1 and 2 diabetes.

KW - Basal insulin

KW - Insulin detemir

KW - Insulin glargine

KW - NPH insulin

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=48949084232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48949084232&partnerID=8YFLogxK

U2 - 10.2217/14750708.5.4.513

DO - 10.2217/14750708.5.4.513

M3 - Article

AN - SCOPUS:48949084232

VL - 5

SP - 513

EP - 529

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 4

ER -